HKSE - Delayed Quote HKD

Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK)

Compare
3.170
+0.070
+(2.26%)
At close: 4:08:06 PM GMT+8
Currency in CNY All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Total Revenue
575,958
573,137
549,215
466,181
Cost of Revenue
385,930
394,135
363,814
301,848
Gross Profit
190,028
179,002
185,401
164,333
Operating Expense
593,987
554,886
661,410
622,794
Operating Income
-403,959
-375,884
-476,009
-458,461
Net Non Operating Interest Income Expense
39,181
40,223
20,203
26,029
Pretax Income
-367,164
-356,364
-422,581
-479,605
Tax Provision
15
15
--
6
Net Income Common Stockholders
-359,010
-346,778
-412,907
-479,611
Diluted NI Available to Com Stockholders
-359,010
-346,778
-412,907
-479,611
Basic EPS
-0.64
-0.62
-0.74
-0.86
Diluted EPS
-0.64
-0.62
-0.74
-0.86
Basic Average Shares
560,416.600
560,416.600
560,416.600
560,416.600
Diluted Average Shares
560,416.600
560,416.600
560,416.600
560,416.600
Total Operating Income as Reported
-406,345
-396,587
-442,784
-505,634
Total Expenses
979,917
949,021
1,025,224
924,642
Net Income from Continuing & Discontinued Operation
-359,010
-346,778
-412,907
-479,611
Normalized Income
-346,044
-325,969.250
-393,539
-450,734.500
Interest Income
40,231
41,654
22,884
28,738
Interest Expense
1,050
1,431
2,681
2,709
Net Interest Income
39,181
40,223
20,203
26,029
EBIT
-366,114
-354,933
-419,900
-476,896
EBITDA
-314,266
-302,971
-364,375
-440,390
Reconciled Cost of Revenue
385,930
394,135
363,814
301,848
Reconciled Depreciation
51,848
51,962
55,525
36,506
Net Income from Continuing Operation Net Minority Interest
-359,010
-346,778
-412,907
-479,611
Total Unusual Items Excluding Goodwill
-17,288
-27,745
-19,368
-38,502
Total Unusual Items
-17,288
-27,745
-19,368
-38,502
Normalized EBITDA
-296,978
-275,226
-345,007
-401,888
Tax Rate for Calcs
0
0
--
0
Tax Effect of Unusual Items
-4,322
-6,936.250
--
-9,625.500
12/31/2021 - 10/8/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade